Objective:
To develop a child-friendly formulation of praziquantel for treating schistosomiasis specifically in preschool-aged children, addressing their unique needs.
Key Findings:
- Praziquantel is effective for school-aged children but unsuitable for preschoolers due to large tablet size and bitter taste.
- The new formulation received positive scientific opinion from EMA in December 2023 and WHO prequalification in May 2024, and was included in the WHO Essential Medicine List in September 2025.
- The first treatments were administered in Uganda in March 2025.
Interpretation:
The tailored formulation addresses significant barriers to treatment adherence in young children, potentially reducing the public health burden of schistosomiasis and improving health outcomes.
Limitations:
- Limited prior experience in pediatric medication development within Astellas may hinder rapid progress.
- Challenges in taste perception across different populations could affect the formulation's acceptance.
Conclusion:
The development of a child-friendly praziquantel formulation represents a significant advancement in treating schistosomiasis in young children, with the potential to save lives and improve public health outcomes through collaborative efforts.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
